The effect of Celecoxib in the treatment of Schizophrenia
Phase 3
Recruiting
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20210831052351N1
- Lead Sponsor
- niversity of social welfare and rehabilitation sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 52
Inclusion Criteria
Patients with schizophrenia in the acute phase
Age range 18 to 65 years
Receiving only one Antipsychotic drug (Risperidone)
IQ greater than 70
Having the consent of the patient and his / her guardian to participate in the research
Exclusion Criteria
Having a debilitating physical illness
patients with depression
Received an electric shock in the last two weeks
History of gastric ulcer or acute gastric bleeding
Pregnancy and lactation
No extra pyramidal symptoms in the study entry based on Simpson-Angus scale
Drug, alcohol or drug abuse in the last 6 months (excluding nicotine)
There is another diagnosis based on DSM5, including mood disorders and mental retardation
Blindness and deafness
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive symptoms of schizophrenia. Timepoint: Every 2 weeks to 8 weeks. Method of measurement: Positive And Negative Syndrome Scale.;Negative symptoms of schizophrenia. Timepoint: Every 2 weeks to 8 weeks. Method of measurement: Positive And Negative Syndrome Scale.;Cognitive symptoms of schizophrenia. Timepoint: Every 2 weeks to 8 weeks. Method of measurement: Montreal Cognitive Assessment Scale.
- Secondary Outcome Measures
Name Time Method Side effects of medications. Timepoint: Every 2 weeks to 8 weeks. Method of measurement: questionnaire.